| Preventing and managing toxicities of high-dose methotrexate SC Howard, J McCormick, CH Pui, RK Buddington, RD Harvey The oncologist 21 (12), 1471-1482, 2016 | 885 | 2016 |
| Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, ... Haematologica 98 (11), 1753, 2013 | 394 | 2013 |
| Withaferin A inhibits breast cancer invasion and metastasis at sub‐cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation JT Thaiparambil, L Bender, T Ganesh, E Kline, P Patel, Y Liu, ... International journal of cancer 129 (11), 2744-2755, 2011 | 316 | 2011 |
| Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma WG Tong, R Chen, W Plunkett, D Siegel, R Sinha, RD Harvey, AZ Badros, ... Journal of clinical oncology 28 (18), 3015-3022, 2010 | 261 | 2010 |
| Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients PG Richardson, R Baz, M Wang, AJ Jakubowiak, JP Laubach, RD Harvey, ... Blood, The Journal of the American Society of Hematology 124 (7), 1038-1046, 2014 | 237 | 2014 |
| Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: findings from an American Society of Clinical Oncology Survey DM Waterhouse, RD Harvey, P Hurley, LA Levit, ES Kim, HD Klepin, ... JCO Oncology Practice 16 (7), 417-421, 2020 | 215 | 2020 |
| Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed/refractory multiple myeloma or lymphoma JJ Shah, AJ Jakubowiak, OA O'Connor, RZ Orlowski, RD Harvey, ... Clinical Cancer Research 22 (1), 34-43, 2016 | 192 | 2016 |
| A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors HH Soliman, E Jackson, T Neuger, EC Dees, RD Harvey, H Han, ... Oncotarget 5 (18), 8136, 2014 | 182 | 2014 |
| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, ... Journal of Clinical Oncology 36 (14), 1389-1395, 2018 | 180 | 2018 |
| Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with advanced solid tumors J Sarantopoulos, GI Shapiro, RB Cohen, JW Clark, JS Kauh, GJ Weiss, ... Clinical Cancer Research 22 (4), 847-857, 2016 | 180 | 2016 |
| Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials RD Pentz, M White, RD Harvey, ZL Farmer, Y Liu, C Lewis, ... Cancer 118 (18), 4571-4578, 2012 | 180 | 2012 |
| Clinical cancer advances 2020: annual report on progress against cancer from the American Society of Clinical Oncology MJ Markham, K Wachter, N Agarwal, MM Bertagnolli, SM Chang, W Dale, ... Journal of Clinical Oncology 38 (10), 1081, 2020 | 172 | 2020 |
| Cancer, inflammation, and therapy: effects on cytochrome P450–mediated drug metabolism and implications for novel immunotherapeutic agents RD Harvey, ET Morgan Clinical Pharmacology & Therapeutics 96 (4), 449-457, 2014 | 163 | 2014 |
| The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, ... Cancer 125 (1), 127-134, 2019 | 148 | 2019 |
| Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single … DC Qian, T Kleber, B Brammer, KM Xu, JM Switchenko, ... The Lancet Oncology 22 (12), 1777-1786, 2021 | 136 | 2021 |
| American Society of Clinical Oncology statement: biosimilars in oncology GH Lyman, E Balaban, M Diaz, A Ferris, A Tsao, E Voest, R Zon, ... Journal of Clinical Oncology 36 (12), 1260-1265, 2018 | 122 | 2018 |
| A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose-and schedule-finding study S Lonial, J Kaufman, M Tighiouart, A Nooka, AA Langston, LT Heffner, ... Clinical Cancer Research 16 (20), 5079-5086, 2010 | 122 | 2010 |
| Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, ... BMC cancer 19, 1-8, 2019 | 115 | 2019 |
| Immunologic and clinical effects of targeting PD‐1 in lung cancer RD Harvey Clinical Pharmacology & Therapeutics 96 (2), 214-223, 2014 | 114 | 2014 |
| In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial DT Koura, JT Horan, AA Langston, M Qayed, A Mehta, HJ Khoury, ... Biology of Blood and Marrow Transplantation 19 (11), 1638-1649, 2013 | 114 | 2013 |
